1 / 23

Thromboelastography

Thromboelastography. Dr. S. Parthasarathy MD., DA., DNB, MD ( Acu ), Dip. Diab . DCA, Dip. Software statistics PhD ( physio ) Mahatma Gandhi medical college and research institute , puducherry – India . What is it and when started .

saskia
Download Presentation

Thromboelastography

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thromboelastography Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab. DCA, Dip. Software statistics PhD (physio) Mahatma Gandhi medical college and research institute , puducherry – India

  2. What is it and when started • Thromboelastographyis a point-of-care global hemostasis system used by anaesthetists largely to monitor perioperative changes in coagulation in surgical patients • It was first developed by the German Dr. HellmutHartert at University of Heidelberg School of Medicine. in 1948

  3. Thromboelastography machine

  4. Indications • Cardiac Surgery • Patient factors(aspirin,clopidogrel,heparin, clotting disorders) • Vascular Surgery. • Major obs. Haemorrhage • Regional on heparin • liver transplantation

  5. What does it test ?? • The visco elastic changes that occur during the hemostaticprocess • TEG provides a real-time functional evaluation of the coagulation cascade, • Platelet function • Clot formation • clot strengthening and fibrin cross-linkage • clot lysis

  6. classical thromboelastography • a small sample of blood is placed into a cuvette (cup) rotated gently to imitate sluggish venous flow and activate coagulation. • When a sensor shaft is inserted into the sample a clot forms between the cup and the sensor. • The speed and strength of clot formation is measured depends on the activity of the plasmatic coagulation system, platelet function, fibrinolysis and other factors

  7. Principle

  8. Values • the R value - time until the first evidence of a clot is detected • The K value - the end of R until the clot reaches 20mm and this represents the speed of clot formation • The angle is the tangent of the curve made as the K is reached and offers similar information to K • The MA is a reflection of clot strength. • Clot lysis time

  9. R value • R: R time is the period of latency from the time that the bloodwas placed in the TEG analyzer until the initial fibrin formation.This represents the enzymatic portion of coagulation. (clotting factors ) 4 – 8 minutes • R = 11 – 14 min – FFP 8 ml/kg • R > 14 FFP 15 ml/Kg

  10. Prolonged R • Shortened R • Hypercoagulable state and early DIC

  11. K: K time is a measure of the speed to reach a certain levelof clot strength. This represents clot kinetics. • 1 – 4 minutes • alpha : measures the rapidity of fibrin built up and cross-linking(clot strengthening). This represents fibrinogen level. • 45 – 75 deg

  12. R normal • K prolonged • Platelet defect

  13. MA: MA or maximum amplitude, is a direct function of the maximumdynamic properties of the fibrin and platelet bonding via GPIIb/IIIaand represents the ultimate strength of the fibrin clot. • 55 – 70 mm • 80 % platelets • 20 % fibrinogen

  14. Decrease and continuous decrease • Platelet deficiency • Primary fibrinolysis

  15. LY30: LY30 measures the rate of amplitude reduction 30 minafter MA. This represents clot lysis. • Normal = 7.5 %

  16. Primary fibrinolysis > 7.5 %

  17. TO SUMMARIZE • Cuvette pin 0.3 ml blood • Visco elastic properties • Full coagulation profile • R, K ,MA , LY 30 • Disease s

  18. TEG with heparinase • heparinase (an enzyme breaking heparin) • “heparinized” patients, prior to heparin reversal with protamine. • This test may prove particularly useful during long pump runs, deep hypothermia, use of ventricular assist devices or complicated major vascular cases • The test will also detect if more protamine is needed to fully reverse heparin.

  19. To remove platelet effect • Add recently FDA approved monoclonal antibody which binds to the platelet GPIIb/IIIa receptors, to the TEG sample • eliminate platelet function from the thromboelastogram • The MA will become a function of fibrinogen activity

  20. Various diseases – TEG

  21. The Sonoclot • provides an alternative visco elastic measure of coagulation. • In contrast to the TEG, Sonoclot immerses a rapidly vibrating probe into a 0.4-mL sample of blood. • As clot formation occurs, impedance to probe movement through the blood increases and generates an electrical signal and characteristic clot “signature.” • The Sonoclot may be used to derive the ACT, as well as to provide information regarding clot strength and fibrinolysis.

  22. Treat the patient than TEG • Thank you all

More Related